PURPOSE: Considerable uncertainty exists regarding relative effects of allogeneic peripheral blood stem cells transplantation (PBSCT) versus bone marrow transplantation (BMT) on outcomes of patients with hematologic malignancies. PATIENTS AND METHODS: To provide the totality of research evidence related to the effects of PBSCT versus BMT, we conducted an individual-patient data meta-analysis using data from nine randomized trials enrolling 1,111 adult patients. RESULTS: Compared with BMT, PBSCT led to faster neutrophil (odds ratio [OR] = 0.31; 95% CI, 0.25 to 0.38; P < .00001) and platelet engraftment (OR = 0.52; 95% CI, 0.44 to 0.61; P < .00001). PBSCT was associated with a significant increase in the development of grade 3-4 acute graft-versus-host disease (GVHD; OR = 1.39; 95% CI, 1.03 to 1.88) and extensive (47% v 31% at 3 years; OR = 1.89; 95% CI, 1.47 to 2.42; P < .000001) and overall chronic GVHD (68% v 52% at 3 years; OR = 1.92; 95% CI, 1.47 to 2.49; P < .000001), but not grade 2-4 acute GVHD (54% v 53%; P = .49). PBSCT was associated with a decrease in relapse (21% v 27% at 3 years; OR = 0.71; 95% CI, 0.54 to 0.93; P = .01) in both late-stage-(33% v 51% at 3 years; OR = 0.59; 95% CI, 0.38 to 0.93; P = .02) and early-stage-disease patients (16% v 20% at 3 years; OR = 0.69; 95% CI, 0.49 to 0.98; P = .04). Nonrelapse mortality was not different between groups. Overall and disease-free survival were only statistically significantly improved in patients with late-stage disease (overall survival: 46% v 31% at 3 years; OR = 0.64; 95% CI, 0.46 to 0.90; P = .01; disease-free survival: 41% v 27% at 3 years; OR = 0.63 95% CI, 0.45 to 0.87; P = .01). CONCLUSION: PBSCT is associated with a decreased relapse rate in hematologic malignancies and improvement in overall and disease-free survival in patients with late-stage disease. PBSCT is also associated with a significant risk of extensive chronic GVHD.
PURPOSE: Considerable uncertainty exists regarding relative effects of allogeneic peripheral blood stem cells transplantation (PBSCT) versus bone marrow transplantation (BMT) on outcomes of patients with hematologic malignancies. PATIENTS AND METHODS: To provide the totality of research evidence related to the effects of PBSCT versus BMT, we conducted an individual-patient data meta-analysis using data from nine randomized trials enrolling 1,111 adult patients. RESULTS: Compared with BMT, PBSCT led to faster neutrophil (odds ratio [OR] = 0.31; 95% CI, 0.25 to 0.38; P < .00001) and platelet engraftment (OR = 0.52; 95% CI, 0.44 to 0.61; P < .00001). PBSCT was associated with a significant increase in the development of grade 3-4 acute graft-versus-host disease (GVHD; OR = 1.39; 95% CI, 1.03 to 1.88) and extensive (47% v 31% at 3 years; OR = 1.89; 95% CI, 1.47 to 2.42; P < .000001) and overall chronic GVHD (68% v 52% at 3 years; OR = 1.92; 95% CI, 1.47 to 2.49; P < .000001), but not grade 2-4 acute GVHD (54% v 53%; P = .49). PBSCT was associated with a decrease in relapse (21% v 27% at 3 years; OR = 0.71; 95% CI, 0.54 to 0.93; P = .01) in both late-stage-(33% v 51% at 3 years; OR = 0.59; 95% CI, 0.38 to 0.93; P = .02) and early-stage-disease patients (16% v 20% at 3 years; OR = 0.69; 95% CI, 0.49 to 0.98; P = .04). Nonrelapse mortality was not different between groups. Overall and disease-free survival were only statistically significantly improved in patients with late-stage disease (overall survival: 46% v 31% at 3 years; OR = 0.64; 95% CI, 0.46 to 0.90; P = .01; disease-free survival: 41% v 27% at 3 years; OR = 0.63 95% CI, 0.45 to 0.87; P = .01). CONCLUSION: PBSCT is associated with a decreased relapse rate in hematologic malignancies and improvement in overall and disease-free survival in patients with late-stage disease. PBSCT is also associated with a significant risk of extensive chronic GVHD.
Authors: A C Vigorito; W M Azevedo; J F Marques; A M Azevedo; K A Eid; F J Aranha; I Lorand-Metze; G B Oliveira; M E Correa; A R Reis; E C Miranda; C A de Souza Journal: Bone Marrow Transplant Date: 1998-12 Impact factor: 5.483
Authors: Jan J Cornelissen; Bronno van der Holt; Eefke J Petersen; Lars Vindelov; Charlotte A Russel; Martin Höglund; Johan Maertens; Harry C Schouten; Eric Braakman; Monique M C Steijaert; Mark J M Zijlmans; Ineke Slaper-Cortenbach; Marc A Boogaerts; Bob Löwenberg; Leo F Verdonck Journal: Exp Hematol Date: 2003-10 Impact factor: 3.084
Authors: W I Bensinger; R Clift; P Martin; F R Appelbaum; T Demirer; T Gooley; K Lilleby; S Rowley; J Sanders; R Storb; C D Buckner Journal: Blood Date: 1996-10-01 Impact factor: 22.113
Authors: Marco Mielcarek; Barry Storer; Paul J Martin; Stephen J Forman; Robert S Negrin; Mary E Flowers; Yoshihiro Inamoto; Thomas R Chauncey; Rainer Storb; Frederick R Appelbaum; William I Bensinger Journal: Blood Date: 2012-02-03 Impact factor: 22.113
Authors: Leslie S Kean; Sharon Sen; Olusegun Onabajo; Karnail Singh; Jennifer Robertson; Linda Stempora; Aylin C Bonifacino; Mark E Metzger; Daniel E L Promislow; Joseph J Mattapallil; Robert E Donahue Journal: Blood Date: 2011-10-11 Impact factor: 22.113
Authors: Yoshihiro Inamoto; Mary E D Flowers; Frederick R Appelbaum; Paul A Carpenter; H Joachim Deeg; Terry Furlong; Hans-Peter Kiem; Marco Mielcarek; Richard A Nash; Rainer F Storb; Robert P Witherspoon; Barry E Storer; Paul J Martin Journal: Biol Blood Marrow Transplant Date: 2011-03-21 Impact factor: 5.742
Authors: Ann A Jakubowski; Trudy N Small; James W Young; Nancy A Kernan; Hugo Castro-Malaspina; Katherine C Hsu; Miguel-Angel Perales; Nancy Collins; Christine Cisek; Michelle Chiu; Marcel R M van den Brink; Richard J O'Reilly; Esperanza B Papadopoulos Journal: Blood Date: 2007-08-23 Impact factor: 22.113
Authors: Nahid Rashid; Michael Slade; Ramzi Abboud; Feng Gao; John F DiPersio; Peter Westervelt; Geoffrey Uy; Keith Stockerl-Goldstein; Rizwan Romee; Mark A Schroeder Journal: Transpl Int Date: 2020-06-19 Impact factor: 3.782
Authors: Laëtitia Le Texier; Katie E Lineburg; Benjamin Cao; Cameron McDonald-Hyman; Lucie Leveque-El Mouttie; Jemma Nicholls; Michelle Melino; Blessy C Nalkurthi; Kylie A Alexander; Bianca Teal; Stephen J Blake; Fernando Souza-Fonseca-Guimaraes; Christian R Engwerda; Rachel D Kuns; Steven W Lane; Michele Teng; Charis Teh; Daniel Gray; Andrew D Clouston; Susan K Nilsson; Bruce R Blazar; Geoffrey R Hill; Kelli Pa MacDonald Journal: JCI Insight Date: 2016-09-22
Authors: P V O'Donnell; M Eapen; M M Horowitz; B R Logan; A DiGilio; C Brunstein; E J Fuchs; M E D Flowers; R Salit; K Raj; A Pagliuca; K Bradstock; A Granata; L Castagna; S Furst; D Blaise Journal: Bone Marrow Transplant Date: 2016-08-15 Impact factor: 5.483